BEZ235 Trial in Patients With Advanced Endometrial Carcinoma

Inclusion Criteria: * Female ≥ 18 years * Histological confirmed diagnosis of advanced endometrial carcinoma with available tissue specimen, either archival tissue or fresh formalin fixed tumor biopsy * Objective and radiologically confirmed progression of disease after prior first-line treatment * Recovery (to grade ≤ 1) from all clinically significant toxicities related to prior therapies (except alopecia) with adequate bone marrow and organ functions * At least one measurable lesion as per RECIST * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 Exclusion Criteria: * Previous treatment with PI3K and/or mammalian Target Of Rapamycin (mTOR) inhibitors * More than one line of prior treatment for advanced or metastatic disease * Active uncontrolled or symptomatic Central Nervous System (CNS) metastases * Concurrent malignancy or malignancy in the last 3 years prior to start of study treatment * Wide field radiotherapy ≤ 28 days or limited field radiation for palliation ≤ 14 days prior to enrollment in this study * Active cardiac disease (e.g. Left Ventricular Ejection Fraction (LVEF) \< 50%, Q-T interval corrected for heart rate (QTcF) \> 480 msec on screening Electrocardiogram (ECG), unstable angina pectoris, ventricular, supraventricular or nodal arrhythmias) * Inadequately controlled hypertension * Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BEZ235 * Drugs with a known risk to induce Torsades de Pointes, moderate and strong inhibitors or inducers of CYP3A4, warfarin and coumadin analogues, Luteinizing Hormone-Releasing Hormone (LHRH) agonists * Pregnant or nursing (lactating) woman Other protocol-defined inclusion/exclusion criteria may apply